Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Next Previous
X
Search
Trial Profile

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; TransCon TLR7/8 Agonist (Primary)
  • Indications Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Penile cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms transcendIT-101
  • Sponsors Ascendis Pharma

    • Most Recent Events

    • 30 Oct 2024 Status changed from recruiting to active, no longer recruiting.
    • 07 Feb 2024 According to an Ascendis Pharma media release, clinical update from dose expansion cohort fourth quarter of 2024.
    • 25 Jan 2024 This study has been discontinued in Poland, according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top